Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures (2017 - 2025)

Historic Gains from Sales and Divestitures for Enanta Pharmaceuticals (ENTA) over the last 9 years, with Q3 2025 value amounting to $152000.0.

  • Enanta Pharmaceuticals' Gains from Sales and Divestitures rose 2459.02% to $152000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $152000.0, marking a year-over-year increase of 2459.02%. This contributed to the annual value of $152000.0 for FY2025, which is 2459.02% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Gains from Sales and Divestitures stood at $152000.0, which was up 2459.02% from $146000.0 recorded in Q2 2025.
  • Enanta Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $152000.0 during Q3 2025, with a 5-year trough of $29000.0 in Q4 2021.
  • Its 5-year average for Gains from Sales and Divestitures is $82842.1, with a median of $70000.0 in 2023.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first plummeted by 3555.56% in 2021, then skyrocketed by 14137.93% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $29000.0 in 2021, then surged by 93.1% to $56000.0 in 2022, then soared by 107.14% to $116000.0 in 2023, then grew by 24.14% to $144000.0 in 2024, then increased by 5.56% to $152000.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $152000.0 for Q3 2025, versus $146000.0 for Q2 2025 and $145000.0 for Q1 2025.